Core Viewpoint - Chronic sinusitis with nasal polyps is a prevalent condition in China, affecting approximately 100 million people, with 20 to 30 million patients experiencing nasal polyps, which significantly impacts their quality of life [1][2]. Group 1: Disease Prevalence and Symptoms - The prevalence of chronic sinusitis in China is estimated to be around 8%, translating to about 100 million patients [1]. - Common symptoms include nasal congestion, purulent nasal discharge, olfactory/taste reduction, and facial pain, which can severely affect patients' quality of life [1][2]. Group 2: Treatment Approaches - The primary treatment strategy combines corticosteroid medication and surgical intervention, but the management of chronic sinusitis with nasal polyps is challenging due to high recurrence rates [1][3]. - Surgical removal of nasal polyps aims to restore normal airflow and drainage, but it does not guarantee a permanent solution, necessitating ongoing medication and follow-up care [3][4]. Group 3: Advances in Treatment - The emergence of biologic therapies represents a significant advancement in treatment, allowing for more precise and effective management of the disease by targeting the underlying inflammatory mechanisms [4][5]. - Biologic agents focus on key inflammatory pathways associated with type 2 inflammation, which is relevant for patients with chronic sinusitis, nasal polyps, asthma, and other comorbidities [5].